文献速递预防保健、筛查与疫苗慢病管理

低剂量CT筛查与美国肺癌分期迁移及生存的关联:准实验研究

Association of computed tomography screening with lung cancer stage shift and survival in the United States: quasi-experimental study.
PubMed 文献 · BMJ · 2022-03-30

该准实验研究利用美国国家癌症数据库和SEER数据库,分析2010至2018年45-80岁非小细胞肺癌患者。2013年引入低剂量CT筛查后,55-80岁人群I期诊断比例自2014年起每年增加3.9%,中位生存每年增加11.9%,但非白人和贫困地区人群I期诊断率仍较低。

要点

  • 2013年引入低剂量CT筛查后,55-80岁人群I期NSCLC诊断比例每年增加3.9%。
  • 同期55-80岁患者中位总生存每年增加11.9%,2014年后死亡风险下降更快。
  • 非白人和低收入/低教育地区人群诊断时IV期比例仍较高。

核心结论

  • 2013年低剂量CT筛查引入后,美国55-80岁人群NSCLC出现向I期迁移,并伴随生存改善。
  • 非白人患者和居住于贫困地区者I期诊断率较低,提示需增加筛查可及性。

研究设计与样本

  • 准实验研究,采用Joinpoint模型、多变量有序logistic回归和多变量Cox比例风险模型。

主要发现

  • 55-80岁人群I期NSCLC诊断比例从2010年27.8%至2013年29.4%无显著增加,2014至2018年每年增加3.9%(95%CI 3.0%至4.8%),从30.2%升至35.5%。
  • 多变量调整后,2014至2018年每年诊断时低一个分期的比值增加比2010至2013年高6.2%(OR 1.062,95%CI 1.048至1.077;P<0.001)。
  • 55-80岁患者中位总生存从2010年15.8个月至2013年18.1个月无显著增加,2014至2018年每年增加11.9%(95%CI 8.9%至15.0%),从19.7个月升至28.2个月。
  • 2014年后死亡风险下降速度显著快于2014年前(P<0.001)。

关键数值与推荐

  • 2018年,非西班牙裔白人和最高收入或最佳教育地区人群中I期NSCLC成为主要诊断。
  • 非白人和低收入或低教育地区人群诊断时仍更可能为IV期。

临床怎么用

  • 全科医生应关注55-80岁高危人群的低剂量CT筛查推荐,以促进早期诊断。
  • 对非白人和贫困地区人群,应主动评估筛查障碍并提高筛查可及性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To determine the effect of the introduction of low dose computed tomography screening in 2013 on lung cancer stage shift, survival, and disparities in the stage of lung cancer diagnosed in the United States. DESIGN: Quasi-experimental study using Joinpoint modeling, multivariable ordinal logistic regression, and multivariable Cox proportional hazards modeling. SETTING: US National Cancer Database and Surveillance Epidemiology End Results program database. PARTICIPANTS: Patients aged 45-80 years diagnosed as having non-small cell lung cancer (NSCLC) between 1 January 2010 and 31 December 2018. MAIN OUTCOME MEASURES: Annual per cent change in percentage of stage I NSCLC diagnosed among patients aged 45-54 (ineligible for screening) and 55-80 (potentially eligible for screening), median all cause survival, and incidence of NSCLC; multivariable adjusted odds ratios for year-to-year changes in likelihood of having earlier stages of disease at diagnosis and multivariable adjusted hazard ratios for changes in hazard of death before versus after introduction of screening. RESULTS: The percentage of stage I NSCLC diagnosed among patients aged 55-80 did not significantly increase from 2010 to 2013 (from 27.8% to 29.4%) and then increased at 3.9% (95% confidence interval 3.0% to 4.8%) per year from 2014 to 2018 (from 30.2% to 35.5%). In multivariable adjusted analysis, the increase in the odds per year of a patient having one lung cancer stage lower at diagnosis during the time period from 2014 to 2018 was 6.2% (multivariable adjusted odds ratio 1.062, 95% confidence interval 1.048 to 1.077; P<0.001) higher than the increase in the odds per year from 2010 to 2013. Similarly, the median all cause survival of patients aged 55-80 did not significantly increase from 2010 to 2013 (from 15.8 to 18.1 months), and then increased at 11.9% (8.9% to 15.0%) per year from 2014 to 2018 (from 19.7 to 28.2 months). In multivariable adjusted analysis, the hazard of death decreased significantly faster after 2014 compared with before 2014 (P<0.001). By 2018, stage I NSCLC was the predominant diagnosis among non-Hispanic white people and people living in the highest income or best educated regions. Non-white people and those living in lower income or less educated regions remained more likely to have stage IV disease at diagnosis. Increases in the detection of early stage disease in the US from 2014 to 2018 led to an estimated 10 100 averted deaths. CONCLUSIONS: A recent stage shift toward stage I NSCLC coincides with improved survival and the introduction of lung cancer screening. Non-white patients and those living in areas of greater deprivation had lower rates of stage I disease identified, highlighting the need for efforts to increase access to screening in the US.

来源:BMJ,查看原文。版权归原作者所有。

引用

  1. Potter AL, Rosenstein AL, Kiang MV, et al. Association of computed tomography screening with lung cancer stage shift and survival in the United States: quasi-experimental study. BMJ. 2022. PMID: 35354556. doi:10.1136/bmj-2021-069008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。